PARIS--(EON: Enhanced Online News)--EOS imaging (Paris:EOSI)(NYSE Euronext, FR0011191766-EOSI), the pioneer in orthopedic 2D/3D imaging, today announced the launch of a new Micro Dose feature for paediatric imaging at the 2013 Journées Françaises de Radiologie (JFR). This announcement is supported by a data presentation on Sunday highlighting the breakthrough in dose reduction.
“Ultra low dose imaging for the follow up of idiopathic scoliosis.”
Every day, people are exposed to minimal levels of naturally-occurring radiation from their surroundings. However, over the past two decades, levels of radiation exposure from artificial sources – primarily from medical imaging – has increased by 600%1. Children in particular face potential adverse effects from excessive medical radiation, including an increased risk of radiation-induced cancer later in life2, and those children that suffer from specific conditions, such as scoliosis, can receive very high levels of radiation3.
EOS already offers a low dose image capability for diagnosis, treatment planning and monitoring in children. This existing offering exposes children to six to nine times less radiation than Computer Radiography with equal or better resulting image quality4. The new EOS Micro Dose feature unveiled at JFR affords up to seven times less radiation than the company’s current low dose offering.
Preliminary findings proving the effectiveness of Micro Dose will be presented at JFR by Dr Marianne Alison of Robert Debré Hospital in Paris in her presentation, titled, “Ultra low dose imaging for the follow up of idiopathic scoliosis.” Dr Alison and her team conducted a study with EOS Micro Dose which was the basis of these findings.
“The EOS imaging system already holds a clear advantage in the continued assessment of children with radiographs because it is the lowest-dose 2D imaging offering available,” said Professor Guy Sebag, Pediatric Imaging Department Head of Robert Debré Hospital and EOS user. “Micro Dose will now afford physicians the safest imaging technology possible to monitor disease progression, in particular in pathologies which require frequent monitoring. At these extremely low dose levels there will be no more second thoughts onto whether we should or not take a control exam if we think it is necessary, and parents will also be reassured that we are not taking any risk for their child”.
EOS Micro Dose feature will be proposed as an option in all new EOS imaging system installations as well as in existing systems.
Marie Meynadier, CEO of EOS imaging, said, “To bring the dose level of a pediatric radiograph to the level of days of natural background radiation on earth is for our physician customers, for their patients and for ourselves a fantastic achievement in the ALARA (As Low As Reasonably Achievable) principle. EOS’ progression from Low Dose to Micro Dose imaging highlights the original principle behind our Nobel Prize-winning detection technology – to plan and monitor orthopaedic treatments using the lowest possible dose of radiation with the best possible image quality”.
For further information about the Company or EOS®, the first full-body, low-dose 3D imaging system, please visit www.eos‐imaging.com.
1 Use of Diagnostic Imaging Studies and Associated Radiation Exposure for Patients Enrolled in Large Integrated Health Care Systems, 1996-2010, American Medical Association, 2012
2 Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Berrington de Gonzalez & Al, Lancet. 2012 Aug 4; 380(9840):499-505. Epub 2012 Jun 7.
3 Ionizing radiation exposure in early onset scoliosis EOS patients treated with rib-based distraction. Nelson Astur & Al. SRS 2012
4 Deschenes S, Charron G, Beaudoin G, Labelle H, Dubois J, Miron MC, Parent S.- Spine (Phila Pa 1976)2010 Apr 20;35(9):989-94.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Backed by an installed base of 70 sites and more than 400 000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group posted 2012 consolidated revenue of €9.42 million and employs 70 people including an R&D team of 25 engineers. The Group is based in Paris and holds three subsidiaries in Cambridge (Massachusetts), in Canada at Montreal and in Germany, and offices in Singapore.
EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: Annual results 2013 on January 22, 2014 (after market).